The Ligand PD-L1 is one of the most important targets for cancer immunotherapy with checkpoint inhibitors. But not all tumors have sufficient quantities of PD-L1 ligands on their surface. Scientists from the German Cancer Consortium (DKTK) have now shown that different types of cancer possess different quantities of PD-L1-Gen copies. Genetic analysis of the PD-L1 gene may in the future help to…
Many drug treatments do not work due to their poor ability to reach their intended targets inside patients’ cells. To address this, researchers at Cardiff University’s Schools of Pharmacy and Pharmaceutical Sciences, and Biosciences have designed a highly efficient method to improve the delivery of therapeutic molecules into diseased cells such as those in stomach cancer, breast cancer and…
Researchers at Massachusetts Institute of Technology research center in Singapore have developed a new microfluidic device that tests the effects of electric fields on cancer cells. They observed that a range of low-intensity, middle-frequency electric fields effectively stopped breast and lung cancer cells from growing and spreading, while having no adverse effect on neighboring healthy cells.
When an immune T cell divides into two daughter cells, the activity of an enzyme called mTORC1, which controls protein production, splits unevenly between the progeny, producing two cells with different properties. Such "asymmetric division," uncovered by Johns Hopkins Kimmel Cancer Center researchers using lab-grown cells and specially bred mice, could offer new ways to enhance cancer…
A new nano-fabricated platform for observing brain cancer cells provides a much more detailed look at how the cells migrate and a more accurate post-surgery prognosis for brain cancer (glioblastoma) patients.
Breast tomosynthesis imaging, Hologic calls it 3-D mammography, is proving to be the best modality to image breast cancer. ‘The Hologic tomosynthesis system has demonstrated superior clinical performance to conventional 2-D mammography in a number of metrics, in particular showing improved detection of invasive cancers and reductions in recall rate,’ the manufacturer reports, adding: ‘Now…
Leading oncologists from across Europe and the UK have joined the debate over the British referendum on whether to leave the EU, adding their support to the campaign to remain in the European Union. Report: Mark Nicholls
CarThera, a French company based at the Brain and Spine Institute (ICM), that designs and develops innovative ultrasound-based medical devices to treat brain disorders, announces the publication on initial successes in disrupting the blood-brain barrier (BBB) with the use of ultrasound. This has been achieved in association with teams from the Assistance Publique-Hôpitaux de Paris (the Greater…
Hepatitis B virus (HBV) causes hepatitis B, an infectious disease that afflicts 230 million people worldwide, thereof 440 000 in Germany. Persistence of the virus in liver cells leads to progressive organ damage in the patient and contributes to a high risk of cirrhosis and liver cancer development. Providing a new paradigm to hepatitis B understanding, researchers at the German Cancer Research…
Cancer researchers from the Würzburg University, in cooperation with the international Cancer Genome Atlas Research Network, have identified new genetic drivers of adrenal cancer. Würzburg was the center of coordination of the European scientists.
The group of Russian and French researchers, with the participation of scientists from the Lomonosov Moscow State University, has succeeded to synthesize nanoparticles of ultrapure silicon, which exhibited the property of efficient photoluminescence, i.e., secondary light emission after photoexcitation. These particles were able to easily penetrate into cancer cells and it allowed to use them as…
A team from the International School for Advanced Studies (SISSA) in Trieste has obtained very promising results by applying gene therapy to glioblastoma. Tests in vitro and in vivo on mice provided very clear-cut results, and modelling demonstrates that the treatment targets at least six different points of tumour metabolism. Gene therapy, a technique that selectively attacks a tumour, might…
In brief, the new method involves exposing cells to ultrasound when they flow through a so-called micro-channel inside a chip. The individual cells are separated in the acoustic field and by studying the cells’ lateral movement at the end of the channel it is possible to identify the acoustic properties of the cells. Conversely, if you know the cells’ acoustic characteristics, you can detect…
Cancer accounts for 13 percent of all deaths worldwide and despite recent medical improvements remains one of the most deadly diseases in the world. Early detection, usually through advanced medical imaging, is crucial as it increases the chances of survival and the potential for full recovery. The EU-funded project GlucoCEST Imaging of Neoplastic Tumours (GLINT) will develop an innovative…
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen’s University Belfast.
Last year, scientists at the University of California San Francisco (UCSF) revealed that by measuring the proportion of both immune and cancerous cells in tumours, or ‘tumour purity,’ clinicians could more precisely predict the success of certain precision therapies. A key aspect of the discovery was access to over 10,000 samples constituting 21 different cancers.
No self-respecting TV crime series is without a pathologist – but the fictitious pathologist who incessantly solves crimes has little to do with reality.
Several bacterial species have pledged promise in fighting tumors. However, most of them are pathogens. In order to use them as a weapon against cancer and other diseases in humans, researchers must find a balance between their therapeutic aggressiveness and safety for the patient. To overcome this problem, researchers at the Helmholtz Centre for Infection Research (HZI) have shifted their focus…
What started as a stuffy-nose and mild cold symptoms for 15-year-old Parker Turchan led to a far more serious diagnosis: a rare type of tumor in his nose and sinuses that extended through his skull near his brain. “He had always been a healthy kid, so we never imagined he had a tumor,” said Parker’s father, Karl. “We didn’t even know you could get a tumor in the back of your nose.”
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin, finds new research in mice led by UCL, Memorial Sloan Kettering (MSK) Cancer Center in New York and the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona.
Imaging research is one step closer to giving clinicians a way to do high-resolution scans of malignant cells in order to diagnose cancer and help identify useful therapies. If this technology were to prove successful in clinical studies, it might change how anatomic pathologists and radiologists diagnose and treat cancer.
Researchers have found that a combination of chemotherapy and modern radiotherapy can benefit patients with advanced nasopharyngeal cancer – a cancer that starts at the back of the nose. These cancers are very rare in the UK and so modern treatments had not been previously studied in patients with advanced disease.
Head and neck cancer patients may no longer have to undergo invasive post-treatment surgery to remove remaining cancer cells, as research shows that innovative scanning-led surveillance can help identify the need for, and guidance of, neck dissection. The study from the Universities of Birmingham and Warwick and University Hospitals Coventry and Warwickshire used advanced imaging to identify…
Johns Hopkins scientists report they have developed an antibody against a specific cellular gateway that suppresses lung tumor cell growth and breast cancer metastasis in transplanted tumor experiments in mice, according to a new study published in the February issue of Nature Communications.
Randox Quality Control are pleased to announce, as part of our ongoing growth and development, the launch of our new Acusera Calibration Verification range for Beckman and Roche Cobas instruments.
